Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Our team reviews your goals, IV options, expected timing, candidacy, and pricing before treatment begins
Orders are typically fulfilled the same or following business day
10.4103/0974-2077.104912 209 SarkarR.ChughS.GargV
This intermediate is subsequently reduced back to its active form through two sequential reactions with glutathione molecules, generating GSSG as a by-product
Under California Vehicle Code 23152, a BAC of 0.08% or more indicates that you are too intoxicated to drive
